The aim of the study is to investigate the safety, tolerability and response of the immune system to the vaccine. For the study, the UMCG is looking for 176 healthy volunteers between the ages of 18 and 65 who want to be vaccinated with this candidate vaccine.
How does the vaccine work?
The Akston Biosciences vaccine is a ‘recombinant subunit vaccine’. This type of vaccine does not use the actual coronavirus (attenuated or live). The vaccine is made up of a portion of the coronavirus, the spike protein, which is fused with a protein fragment of a human antibody. The vaccine is contained in a liquid or adjuvant that enhances the immune response.
The human body knows that the spike protein belongs to the coronavirus and initiates a defense mechanism in which antibodies and T cells are produced. With this technique, a natural reaction against the virus infection is imitated and the own immune system is activated. The advantage of this type of vaccine is that it does not contain any genetic material from the virus and therefore it is impossible for the virus to multiply in the body.
The vaccine has already been extensively tested in animal models for COVID-19 infections, in which it has been shown to be effective and safe. The next phase is to investigate the safety, tolerability and response of the immune system to the vaccine in humans.
The UMCG is looking for 176 healthy volunteers older than 18 and younger than 65 years, who have never had a SARS-CoV-2 infection or received a (candidate) vaccine against corona before. Study participants will receive one or two doses of the candidate vaccine to determine the dose at which you have sufficient antibodies in your body. Participants do not lose the right to receive another corona vaccine at a later date.
UMCG is investigating candidate vaccine against corona and is looking for volunteers
Source link UMCG is investigating candidate vaccine against corona and is looking for volunteers